<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00346918</url>
  </required_header>
  <id_info>
    <org_study_id>EK-1246</org_study_id>
    <nct_id>NCT00346918</nct_id>
  </id_info>
  <brief_title>Sirolimus (Rapamune®) for Autosomal Dominant Polycystic Kidney Disease (ADPKD)</brief_title>
  <official_title>Sirolimus (Rapamune®) for Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD): a Randomized Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to investigate whether Rapamune used at a low dose (2 mg/d) retards
      cyst growth and slows renal functional deterioration in patients with ADPKD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently there is no treatment for ADPKD other than supportive care and blood pressure
      control. Usually dialytic treatment or renal transplantation becomes necessary when the
      disease has progressed to end-stage renal failure.We and others could demonstrate that
      rapamycin, a classical mTOR inhibitor, retards cyst growth and preserves renal function in a
      rodent model of ADPKD. The aim of our study is to investigate whether Rapamune (2 mg/d)
      retards cyst growth and slows renal functional deterioration in patients with ADPKD. We
      anticipate that we can slow disease progression and delay the need for chronic renal
      replacement therapy by the inhibition of mTOR with Rapamune. This is a 24-month prospective,
      controlled, open label study with 2 parallel groups in patients with ADPKD. Patients will be
      randomized at a 1:1 ratio to one of the 2 treatment arms. Primary endpoint is percentage
      change of renal volume measured by high resolution magnetic resolution imaging.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal volume measured by high resolution magnetic resolution imaging</measure>
    <time_frame>1.5 yrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR</measure>
    <time_frame>1.5 yrs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>1.5 yrs</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of hypertension, cyst infections and flank pain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sirolimus plus Standard Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Standard plus Sirolimus</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Rapamune (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard</intervention_name>
    <description>Standard</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Treatment of hypertension, cyst infections and flank pain</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ADPKD patient between 18 and 40 years of age

          -  measured GFR higher than 70 ml/min 1.73m2

          -  documented kidney volume progression

          -  informed consent

        Exclusion Criteria:

          -  Female of childbearing potential who is planning to become pregnant, who is pregnant
             and/or lactating, who is unwilling to use effective means of contraception

          -  increased liver enzymes (2-fold above normal values)

          -  hypercholesterolemia (fasting cholesterol &gt; 8 mmol/l) or hypertriglyceridaemia (&gt; 5
             mmol/l) not controlled by lipid lowering therapy

          -  granulocytopenia (white blood cell &lt; 3,000/mm3) or thrombocytopenia (platelets &lt;
             100,000/mm3),

          -  infection with hepatitis B or C, HIV

          -  any past or present malignancy

          -  mental illness that interfere with the patient ability to comply with the protocol

          -  drug or alcohol abuse within one year of baseline

          -  co-medication with strong inhibitor of CYP3A4 and or P-gp like voriconazole,
             ketoconazole, diltiazem, verapamil, erythromycin

          -  co-medication with strong CYP3A4 and or P-gp inductor like rifampicin

          -  known hypersensitivity to macrolides or Rapamune
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas L. Serra, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Zurich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant. 2006 Mar;21(3):598-604. Epub 2005 Oct 12.</citation>
    <PMID>16221708</PMID>
  </results_reference>
  <results_reference>
    <citation>Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, Rentsch KM, Spanaus KS, Senn O, Kristanto P, Scheffel H, Weishaupt D, Wüthrich RP. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010 Aug 26;363(9):820-9. doi: 10.1056/NEJMoa0907419. Epub 2010 Jun 26.</citation>
    <PMID>20581391</PMID>
  </results_reference>
  <results_reference>
    <citation>Braun M, Young J, Reiner CS, Poster D, Wüthrich RP, Serra AL. Ovarian toxicity from sirolimus. N Engl J Med. 2012 Mar 15;366(11):1062-4. doi: 10.1056/NEJMc1113145.</citation>
    <PMID>22417271</PMID>
  </results_reference>
  <results_reference>
    <citation>Braun M, Young J, Reiner CS, Poster D, Krauer F, Kistler AD, Kristanto P, Wang X, Liu Y, Loffing J, Andreisek G, von Eckardstein A, Senn O, Wüthrich RP, Serra AL. Low-dose oral sirolimus and the risk of menstrual-cycle disturbances and ovarian cysts: analysis of the randomized controlled SUISSE ADPKD trial. PLoS One. 2012;7(10):e45868. doi: 10.1371/journal.pone.0045868. Epub 2012 Oct 10.</citation>
    <PMID>23071528</PMID>
  </results_reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2006</study_first_submitted>
  <study_first_submitted_qc>June 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2006</study_first_posted>
  <last_update_submitted>February 26, 2014</last_update_submitted>
  <last_update_submitted_qc>February 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADPKD</keyword>
  <keyword>autosomal dominant polycystic kidney disease</keyword>
  <keyword>Sirolimus</keyword>
  <keyword>volumetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

